AUG 12, 2026 · PHASE 1 TRIAL
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
ClinicalTrials.gov
Phase 1 dose-escalation trial in early recruitment with no results reported; designed to establish safety and tolerability in a small population with relapsed/refractory solid tumours.
Reported
Planned enrollment30
PhasePhase 1
Primary outcome measureRecommended phase II dose (RP2D) of GPNMB-d…